Published in FDA Law Weekly, May 24th, 2007
On May 8, 2007, Somaxon received correspondence from the U.S. Food and Drug Administration (FDA) in which the FDA stated that the results of the company's ongoing 26-week transgenic mouse carcinogenicity study of SILENOR(TM) should be included as part of the initial New Drug Application (NDA) submission for SILENOR(TM). This request may result in the company delaying its initial NDA submission until the first quarter of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.